|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity |
ISO |
ciglitazone results in decreased activity of ABCB11 protein |
CTD |
PMID:20829430 |
|
NCBI chr 3:74,424,620...74,520,646
|
|
G |
Abhd3 |
abhydrolase domain containing 3, phospholipase |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ABHD3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ABHD3 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr18:1,996,010...2,051,311
|
|
G |
Acaa1a |
acetyl-CoA acyltransferase 1A |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of ACAA1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 8:127,956,126...127,966,348
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACAA2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr18:68,345,136...68,373,246
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACADM mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ACADM mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 2:245,518,693...245,542,864
|
|
G |
Acadvl |
acyl-CoA dehydrogenase, very long chain |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACADVL mRNA |
CTD |
PMID:16197558 |
|
NCBI chr10:55,231,558...55,236,786
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of ACSL1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr16:45,755,246...45,821,541
|
|
G |
Acsm3 |
acyl-CoA synthetase medium-chain family member 3 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACSM3 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:174,133,260...174,159,966
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
ciglitazone inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA] |
CTD |
PMID:18162602 |
|
NCBI chr 1:241,159,723...241,172,503
|
|
G |
Agpat2 |
1-acylglycerol-3-phosphate O-acyltransferase 2 |
increases expression |
ISO |
ciglitazone results in increased expression of AGPAT2 mRNA |
CTD |
PMID:16847310 |
|
NCBI chr 3:29,814,924...29,826,569
|
|
G |
Agt |
angiotensinogen |
decreases response to substance |
EXP |
ciglitazone results in decreased susceptibility to AGT protein modified form |
CTD |
PMID:16820301 |
|
NCBI chr19:69,426,540...69,447,017
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of AKR1C1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AKR1C1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr17:70,720,397...70,747,285
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of AKR1C2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AKR1C2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr17:70,669,684...70,717,935
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases expression |
EXP |
ciglitazone results in decreased expression of ALDH1A1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 1:218,000,470...218,152,962
|
|
G |
Ang |
angiogenin |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ANG mRNA |
CTD |
PMID:16197558 |
|
NCBI chr15:24,312,711...24,323,361
|
|
G |
Angptl4 |
angiopoietin-like 4 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ANGPTL4 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 7:14,550,288...14,557,797
|
|
G |
Apom |
apolipoprotein M |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of APOM mRNA |
CTD |
PMID:16197558 |
|
NCBI chr20:3,690,950...3,693,550
|
|
G |
Aqp1 |
aquaporin 1 |
decreases expression |
EXP |
ciglitazone results in decreased expression of AQP1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 4:85,812,784...85,824,964
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of AQP3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AQP3 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 5:61,035,165...61,040,683
|
|
G |
Arhgef2 |
Rho/Rac guanine nucleotide exchange factor 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ARHGEF2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 2:174,061,126...174,118,355
|
|
G |
Atf7ip2 |
activating transcription factor 7 interacting protein 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ATF7IP2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr10:5,403,099...5,445,989
|
|
G |
Atp1b1 |
ATPase Na+/K+ transporting subunit beta 1 |
decreases expression |
EXP |
ciglitazone results in decreased expression of ATP1B1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr13:76,786,580...76,807,096
|
|
G |
Atp1b3 |
ATPase Na+/K+ transporting subunit beta 3 |
decreases expression |
EXP |
ciglitazone results in decreased expression of ATP1B3 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 8:96,910,265...96,941,592
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression |
EXP |
ciglitazone results in increased expression of BAD protein |
CTD |
PMID:12065618 |
|
NCBI chr 1:213,562,719...213,572,034
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression affects response to substance |
ISO EXP |
[Niflumic Acid co-treated with ciglitazone] results in increased activity of BAX protein; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased activity of BAX protein] ciglitazone results in increased expression of BAX protein BAX mRNA affects the susceptibility to ciglitazone |
CTD |
PMID:12065618 PMID:15492468 PMID:21067863 |
|
NCBI chr 1:105,076,472...105,081,906
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
ciglitazone results in decreased expression of BCL2 protein |
CTD |
PMID:15492468 |
|
NCBI chr13:23,204,464...23,366,900
|
|
G |
Bcl6 |
BCL6, transcription repressor |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of BCL6 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr11:76,854,090...76,877,389
|
|
G |
Bdh1 |
3-hydroxybutyrate dehydrogenase 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of BDH1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr11:69,302,534...69,343,173
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of BHMT mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 2:26,594,852...26,614,429
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of BID protein; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of BID protein] |
CTD |
PMID:21067863 |
|
NCBI chr 4:155,785,366...155,808,775
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
ciglitazone results in decreased expression of BIRC5 |
CTD |
PMID:17940898 |
|
NCBI chr10:103,567,369...103,580,069
|
|
G |
Blvrb |
biliverdin reductase B |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of BLVRB mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:91,866,258...91,883,921
|
|
G |
Cadm1 |
cell adhesion molecule 1 |
decreases expression |
EXP |
ciglitazone results in decreased expression of CADM1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 8:47,847,836...48,178,703
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression |
ISO |
[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP3 protein; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP3 protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP3 protein]; GAST protein inhibits the reaction [ciglitazone results in increased expression of CASP3 mRNA] |
CTD |
PMID:15387324 PMID:21067863 |
|
NCBI chr16:52,395,539...52,413,794
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
ISO |
benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased activity of CASP8 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased activity of CASP8 protein]]; ciglitazone promotes the reaction [Niflumic Acid results in increased activity of CASP8 protein]; DDIT3 mutant form inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased activity of CASP8 protein]]; DDIT3 mutant form inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased activity of CASP8 protein]]; Niflumic Acid promotes the reaction [ciglitazone results in increased activity of CASP8 protein] |
CTD |
PMID:21067863 |
|
NCBI chr 9:67,747,109...67,806,699
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP9 protein; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP9 protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP9 protein] |
CTD |
PMID:21067863 |
|
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of CAT mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 3:110,297,340...110,329,526
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of CCL20 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CCL20 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 9:91,837,139...91,839,736
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
ciglitazone inhibits the reaction [Thioglycolates results in increased secretion of CCL5 protein] |
CTD |
PMID:12624547 |
|
NCBI chr10:68,820,330...68,824,906
|
|
G |
Ccl9 |
C-C motif chemokine ligand 9 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of CCL15 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CCL15 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr10:68,863,994...68,868,928
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
ciglitazone results in decreased expression of CCNA2 protein |
CTD |
PMID:21080969 |
|
NCBI chr 2:121,355,363...121,361,762
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression increases expression |
ISO EXP |
ciglitazone results in decreased expression of CCND1 ciglitazone results in decreased expression of CCND1 protein ciglitazone results in increased expression of CCND1 mRNA |
CTD |
PMID:12787395 PMID:18162602 PMID:20578043 |
|
NCBI chr 1:209,518,288...209,527,986
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions decreases expression |
ISO EXP |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of CDH1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CDH1 mRNA; ciglitazone results in increased expression of and results in increased activity of CDH1 protein ciglitazone results in decreased expression of CDH1 mRNA |
CTD |
PMID:12391285 PMID:16197558 PMID:22193206 |
|
NCBI chr19:51,402,178...51,471,572
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression multiple interactions |
ISO |
ciglitazone results in decreased expression of CDK1 protein CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of CDK1 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of CDK1 protein] |
CTD |
PMID:21080969 |
|
NCBI chr20:19,265,252...19,280,456
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression multiple interactions |
ISO EXP |
ciglitazone results in decreased expression of CDK4 protein CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of CDK4 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of CDK4 protein] ciglitazone results in decreased expression of CDK4 mRNA |
CTD |
PMID:20578043 PMID:21080969 |
|
NCBI chr 7:64,771,453...64,774,891
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression increases expression |
ISO |
ciglitazone results in decreased expression of CDKN1A ciglitazone results in increased expression of CDKN1A protein |
CTD |
PMID:12787395 PMID:19140230 |
|
NCBI chr20:7,150,820...7,161,373
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
EXP |
ciglitazone results in increased expression of CDKN1B mRNA |
CTD |
PMID:20578043 |
|
NCBI chr 4:169,491,273...169,496,500
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression |
EXP |
ciglitazone results in increased expression of CEBPB mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 3:176,817,005...176,818,436
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of CEBPD mRNA |
CTD |
PMID:16197558 |
|
NCBI chr11:84,764,670...84,765,808
|
|
G |
Ces1d |
carboxylesterase 1D |
decreases expression |
ISO |
ciglitazone results in decreased expression of CES1 mRNA |
CTD |
PMID:11409902 |
|
NCBI chr19:30,046,494...30,085,039
|
|
G |
Chmp5 |
charged multivesicular body protein 5 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of CHMP5 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 5:60,877,369...60,894,512
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of CIDEC mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 4:146,569,288...146,582,173
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of CITED2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:12,312,426...12,314,869
|
|
G |
Cobll1 |
cordon-bleu WH2 repeat protein-like 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of COBLL1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 3:49,753,260...49,915,168
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
multiple interactions |
EXP |
ciglitazone inhibits the reaction [Triiodothyronine results in increased expression of COL10A1 mRNA] |
CTD |
PMID:16023420 |
|
NCBI chr20:38,183,103...38,189,488
|
|
G |
Col11a1 |
collagen type XI alpha 1 chain |
decreases expression |
EXP |
ciglitazone results in decreased expression of COL11A1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 2:201,820,715...202,013,853
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
ciglitazone inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27936102 |
|
NCBI chr10:80,380,458...80,397,461
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
decreases expression |
EXP |
ciglitazone results in decreased expression of COL4A1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr16:84,885,597...84,996,482
|
|
G |
Col4a5 |
collagen type IV alpha 5 chain |
decreases expression |
EXP |
ciglitazone results in decreased expression of COL4A5 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr X:109,907,251...110,111,214
|
|
G |
Col5a1 |
collagen type V alpha 1 chain |
decreases expression |
EXP |
ciglitazone results in decreased expression of COL5A1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 3:11,208,429...11,356,715
|
|
G |
Copa |
COPI coat complex subunit alpha |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of COPA mRNA |
CTD |
PMID:16197558 |
|
NCBI chr13:84,546,483...84,586,879
|
|
G |
Cp |
ceruloplasmin |
decreases expression |
EXP |
ciglitazone results in decreased expression of CP mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 2:104,368,336...104,427,119
|
|
G |
Cpm |
carboxypeptidase M |
decreases expression |
EXP |
ciglitazone results in decreased expression of CPM mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 7:53,225,647...53,286,220
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions affects response to substance |
ISO |
ciglitazone inhibits the reaction [CREBBP protein binds to EGFR promoter]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of CDK1 protein]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of CDK4 protein]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of EGFR protein]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of MAPK3 protein]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of MYC protein] CREBBP affects the susceptibility to ciglitazone |
CTD |
PMID:21080969 |
|
NCBI chr10:11,842,307...11,968,266
|
|
G |
Cstb |
cystatin B |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of CSTB mRNA |
CTD |
PMID:16197558 |
|
NCBI chr20:10,245,462...10,247,505
|
|
G |
Ctsc |
cathepsin C |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of CTSC mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:142,028,386...142,059,841
|
|
G |
Cyb5r3 |
cytochrome b5 reductase 3 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of CYB5R3 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 7:116,186,729...116,204,290
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of CYP1A2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CYP1A2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 8:66,971,261...66,978,149
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
ciglitazone promotes the reaction [Niflumic Acid results in increased expression of DDIT3 protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased activity of BAX protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of BID protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP3 protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP9 protein]; DDIT3 mutant form inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased activity of CASP8 protein]]; DDIT3 mutant form inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased cleavage of PARP1 protein]]; DDIT3 mutant form inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased activity of CASP8 protein]]; DDIT3 mutant form inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased cleavage of PARP1 protein]]; DDIT3 results in increased susceptibility to [Niflumic Acid co-treated with ciglitazone]; Niflumic Acid promotes the reaction [ciglitazone results in increased expression of DDIT3 protein] |
CTD |
PMID:21067863 |
|
NCBI chr 7:65,001,695...65,006,517
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
increases expression |
ISO |
ciglitazone results in increased expression of DGAT1 mRNA |
CTD |
PMID:16847310 |
|
NCBI chr 7:110,104,514...110,119,091
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
multiple interactions increases activity |
ISO |
PPARG protein promotes the reaction [ciglitazone results in increased activity of DIO2 protein] |
CTD |
PMID:19036883 |
|
NCBI chr 6:115,396,308...115,410,594
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of DKK1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:237,794,969...237,798,650
|
|
G |
Dlc1 |
DLC1 Rho GTPase activating protein |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of DLC1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr16:55,246,716...55,671,441
|
|
G |
Dnajb5 |
DnaJ heat shock protein family (Hsp40) member B5 |
increases expression |
EXP |
ciglitazone results in increased expression of DNAJB5 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 5:57,176,840...57,186,067
|
|
G |
Dok4 |
docking protein 4 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of DOK4 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of DOK4 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr19:10,152,511...10,163,182
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
EXP |
ciglitazone results in increased expression of DUSP1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr10:17,184,853...17,187,646
|
|
G |
Eeig1 |
estrogen-induced osteoclastogenesis regulator 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of EEIG1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 3:15,822,441...15,854,651
|
|
G |
Efemp1 |
EGF containing fibulin extracellular matrix protein 1 |
decreases expression |
EXP |
ciglitazone results in decreased expression of EFEMP1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr14:106,811,769...106,890,961
|
|
G |
Efna1 |
ephrin A1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of EFNA1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 2:174,681,676...174,689,061
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions decreases expression |
ISO |
ciglitazone inhibits the reaction [CREBBP protein binds to EGFR promoter]; ciglitazone inhibits the reaction [NCOA1 protein binds to EGFR promoter]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of EGFR protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of EGFR protein] |
CTD |
PMID:21080969 |
|
NCBI chr14:95,378,626...95,551,358
|
|
G |
Eif2a |
eukaryotic translation initiation factor 2A |
increases phosphorylation multiple interactions |
ISO |
ciglitazone results in increased phosphorylation of EIF2A protein ciglitazone promotes the reaction [Niflumic Acid results in increased phosphorylation of EIF2A protein]; Niflumic Acid promotes the reaction [ciglitazone results in increased phosphorylation of EIF2A protein] |
CTD |
PMID:21067863 |
|
NCBI chr 2:142,761,303...142,794,767
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases phosphorylation |
ISO |
ciglitazone promotes the reaction [Niflumic Acid results in increased phosphorylation of EIF2AK3 protein]; Niflumic Acid promotes the reaction [ciglitazone results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:21067863 |
|
NCBI chr 4:104,363,838...104,425,271
|
|
G |
Elf5 |
E74 like ETS transcription factor 5 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ELF5 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ELF5 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 3:89,808,837...89,836,977
|
|
G |
Emp1 |
epithelial membrane protein 1 |
increases expression |
EXP |
ciglitazone results in increased expression of EMP1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 4:168,212,901...168,233,039
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of EPAS1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 6:13,543,252...13,626,147
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of FABP1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of FABP1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 4:104,744,302...104,753,119
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression |
ISO |
ciglitazone results in increased expression of FABP4 mRNA |
CTD |
PMID:16847310 |
|
NCBI chr 2:93,488,251...93,492,961
|
|
G |
Fads1 |
fatty acid desaturase 1 |
multiple interactions increases expression |
ISO |
[beta-hydroxy simvastatin acid co-treated with ciglitazone] results in increased expression of FADS1 mRNA ciglitazone results in increased expression of FADS1 mRNA |
CTD |
PMID:17655842 |
|
NCBI chr 1:216,252,605...216,267,618
|
|
G |
Fam13a |
family with sequence similarity 13, member A |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of FAM13A mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of FAM13A mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 4:88,056,521...88,155,782
|
|
G |
Flnb |
filamin B |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of FLNB mRNA |
CTD |
PMID:16197558 |
|
NCBI chr15:16,961,999...17,095,059
|
|
G |
Flnc |
filamin C |
increases expression |
EXP |
ciglitazone results in increased expression of FLNC mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 4:58,999,445...59,027,240
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression increases expression |
ISO EXP |
ciglitazone results in decreased expression of FOS ciglitazone results in increased expression of FOS mRNA |
CTD |
PMID:12787395 PMID:22193206 |
|
NCBI chr 6:110,852,188...110,855,054
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of FOXO1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 2:138,462,974...138,541,420
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
increases expression |
EXP |
ciglitazone results in increased expression of GADD45G mRNA |
CTD |
PMID:22193206 |
|
NCBI chr17:13,528,606...13,530,351
|
|
G |
Galnt2 |
polypeptide N-acetylgalactosaminyltransferase 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of GALNT2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of GALNT2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr19:69,110,657...69,222,237
|
|
G |
Gast |
gastrin |
multiple interactions |
ISO |
GAST protein inhibits the reaction [ciglitazone results in increased expression of CASP3 mRNA] |
CTD |
PMID:15387324 |
|
NCBI chr10:85,264,832...85,269,393
|
|
G |
Gcn1 |
GCN1 activator of EIF2AK4 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of GCN1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr12:46,652,273...46,715,119
|
|
G |
Gk |
glycerol kinase |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of GK mRNA |
CTD |
PMID:16197558 |
|
NCBI chr X:54,106,708...54,189,940
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of GPX3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of GPX3 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr10:39,529,335...39,537,406
|
|
G |
Gramd2b |
GRAM domain containing 2B |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of GRAMD2B mRNA |
CTD |
PMID:16197558 |
|
NCBI chr18:52,082,128...52,180,056
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
decreases expression |
EXP |
ciglitazone results in decreased expression of GSTM2 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 2:195,624,015...195,628,774
|
|
G |
Gys2 |
glycogen synthase 2 |
increases expression |
ISO |
ciglitazone results in increased expression of GYS2 mRNA; ciglitazone results in increased expression of GYS2 protein |
CTD |
PMID:17437057 |
|
NCBI chr 4:175,365,054...175,406,228
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of HADHA mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HADHA mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 6:26,187,969...26,227,605
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of HAMP mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:95,298,332...95,300,271
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
decreases expression |
EXP |
ciglitazone results in decreased expression of HIF1A mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 6:98,357,788...98,405,068
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of HMGCS2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HMGCS2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 2:185,875,609...185,903,505
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of HMOX1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HMOX1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr19:13,452,365...13,479,823
|
|
G |
Hpn |
hepsin |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of HPN mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:86,337,085...86,352,785
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
ISO |
ciglitazone results in decreased expression of ICAM1 mRNA; ciglitazone results in decreased expression of ICAM1 protein |
CTD |
PMID:17425601 |
|
NCBI chr 8:27,829,688...27,841,618
|
|
G |
Ier2 |
immediate early response 2 |
increases expression |
EXP |
ciglitazone results in increased expression of IER2 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr19:23,494,551...23,496,075
|
|
G |
Ifng |
interferon gamma |
multiple interactions decreases secretion |
ISO |
bisphenol A diglycidyl ether inhibits the reaction [ciglitazone results in decreased secretion of IFNG protein]; ciglitazone inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; ciglitazone inhibits the reaction [IFNG protein results in increased expression of IRF1 mRNA]; ciglitazone inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; T 0070907 inhibits the reaction [ciglitazone results in decreased secretion of IFNG protein] |
CTD |
PMID:12847270 PMID:16844232 |
|
NCBI chr 7:55,789,180...55,793,216
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO |
ciglitazone inhibits the reaction [Thioglycolates results in increased secretion of IL1B protein] ciglitazone results in increased expression of [IL1B protein results in increased expression of PTGS2 protein] ciglitazone promotes the reaction [IL1B protein results in increased abundance of Dinoprostone]; Dexamethasone inhibits the reaction [ciglitazone results in increased expression of [IL1B protein results in increased expression of PTGS2 protein]] |
CTD |
PMID:12517972 PMID:12624547 |
|
NCBI chr 3:137,030,200...137,036,581
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of IL1R1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 9:50,000,558...50,076,579
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
ciglitazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]; T 0070907 inhibits the reaction [ciglitazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]] |
CTD |
PMID:21511917 |
|
NCBI chr 2:121,932,968...121,937,672
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; ciglitazone inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Mifepristone inhibits the reaction [ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]] |
CTD |
PMID:15684043 |
|
NCBI chr 4:5,889,999...5,894,575
|
|
G |
Il6st |
interleukin 6 cytokine family signal transducer |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of IL6ST mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 2:45,798,872...45,839,501
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
ISO |
ciglitazone inhibits the reaction [IFNG protein results in increased expression of IRF1 mRNA] |
CTD |
PMID:12847270 |
|
NCBI chr10:38,417,935...38,424,946
|
|
G |
Itgb5 |
integrin subunit beta 5 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of ITGB5 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr11:66,828,428...66,944,231
|
|
G |
Itih3 |
inter-alpha trypsin inhibitor, heavy chain 3 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ITIH3 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr16:6,101,922...6,117,154
|
|
G |
Jag1 |
jagged canonical Notch ligand 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of JAG1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 3:124,406,783...124,442,220
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
EXP ISO |
ciglitazone results in increased expression of JUN mRNA [Bucladesine co-treated with ciglitazone] results in increased expression of and results in increased phosphorylation of JUN protein; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of JUN mRNA]; ciglitazone promotes the reaction [Bucladesine results in increased expression of JUN mRNA] ciglitazone results in increased expression of JUN mRNA; ciglitazone results in increased expression of JUN protein |
CTD |
PMID:19698295 PMID:22193206 |
|
NCBI chr 5:115,009,900...115,012,993
|
|
G |
Klf4 |
KLF transcription factor 4 |
increases expression |
EXP |
ciglitazone results in increased expression of KLF4 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 5:75,074,107...75,079,182
|
|
G |
Lama1 |
laminin subunit alpha 1 |
decreases expression |
EXP |
ciglitazone results in decreased expression of LAMA1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 9:115,139,548...115,263,620
|
|
G |
Lamb2 |
laminin subunit beta 2 |
decreases expression |
EXP |
ciglitazone results in decreased expression of LAMB2 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 8:109,178,367...109,190,552
|
|
G |
Lgals3 |
galectin 3 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of LGALS3 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr15:20,620,083...20,632,019
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
multiple interactions |
ISO |
bisphenol A diglycidyl ether inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; bisphenol A diglycidyl ether inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; T 0070907 inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]] |
CTD |
PMID:19922793 |
|
NCBI chr14:83,354,602...83,364,053
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of LIPC mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of LIPC mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 8:71,509,633...71,635,663
|
|
G |
Lmcd1 |
LIM and cysteine-rich domains 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of LMCD1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 4:145,393,153...145,452,049
|
|
G |
Lox |
lysyl oxidase |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of LOX mRNA |
CTD |
PMID:16197558 |
|
NCBI chr18:45,964,544...45,977,431
|
|
G |
Lpcat1 |
lysophosphatidylcholine acyltransferase 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of LPCAT1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:29,766,070...29,816,401
|
|
G |
Lpcat3 |
lysophosphatidylcholine acyltransferase 3 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of LPCAT3 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 4:157,468,397...157,509,889
|
|
G |
Map4k3 |
mitogen-activated protein kinase kinase kinase kinase 3 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of MAP4K3 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 6:20,029,246...20,198,583
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation increases phosphorylation multiple interactions |
ISO EXP |
ciglitazone results in decreased phosphorylation of MAPK1 protein ciglitazone results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK1 protein]; Glutathione inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:12083801 PMID:19140230 PMID:20578043 |
|
NCBI chr11:97,462,025...97,529,193
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of MAPK14 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr20:6,751,288...6,812,294
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation decreases expression multiple interactions increases phosphorylation |
ISO EXP |
ciglitazone results in decreased phosphorylation of MAPK3 protein ciglitazone results in decreased expression of MAPK3 protein CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of MAPK3 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of MAPK3 protein] ciglitazone results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK3 protein]; Glutathione inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK3 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:12083801 PMID:19140230 PMID:20578043 PMID:21080969 |
|
NCBI chr 1:190,797,189...190,803,411
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of MKI67 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:199,926,150...199,952,847
|
|
G |
Mogat1 |
monoacylglycerol O-acyltransferase 1 |
increases expression |
ISO |
ciglitazone results in increased expression of MOGAT1 mRNA |
CTD |
PMID:16847310 |
|
NCBI chr 9:79,980,963...79,988,513
|
|
G |
Mpc1 |
mitochondrial pyruvate carrier 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of MPC1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:54,985,305...54,996,979
|
|
G |
Mpzl2 |
myelin protein zero-like 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of MPZL2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 8:54,244,920...54,256,064
|
|
G |
Mtmr4 |
myotubularin related protein 4 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of MTMR4 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr10:72,890,665...72,913,598
|
|
G |
Mxra8 |
matrix remodeling associated 8 |
decreases expression |
EXP |
ciglitazone results in decreased expression of MXRA8 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 5:171,731,153...171,735,879
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions decreases expression |
ISO |
CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of MYC protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of MYC protein] |
CTD |
PMID:21080969 |
|
NCBI chr 7:95,483,105...95,488,031
|
|
G |
Ncoa1 |
nuclear receptor coactivator 1 |
multiple interactions affects response to substance |
ISO |
ciglitazone inhibits the reaction [NCOA1 protein binds to EGFR promoter]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of CDK1 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of CDK4 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of EGFR protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of MAPK3 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of MYC protein] NCOA1 affects the susceptibility to ciglitazone |
CTD |
PMID:21080969 |
|
NCBI chr 6:32,952,090...33,229,829
|
|
G |
Ndrg2 |
NDRG family member 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of NDRG2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr15:24,600,981...24,609,621
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions decreases activity |
ISO |
ciglitazone results in decreased activity of [RELA protein binds to NFKB1 protein] ciglitazone results in decreased activity of NFKB1 protein |
CTD |
PMID:17425601 |
|
NCBI chr 2:226,689,745...226,805,897
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
decreases expression |
ISO |
ciglitazone results in decreased expression of NFKBIA protein |
CTD |
PMID:12517972 |
|
NCBI chr 6:78,593,844...78,597,307
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
ciglitazone inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; ciglitazone inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:12031542 PMID:12847270 |
|
NCBI chr10:64,313,335...64,349,221
|
|
G |
Npc1 |
NPC intracellular cholesterol transporter 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of NPC1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr18:3,379,482...3,425,100
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of NR1H3 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 3:97,614,616...97,632,053
|
|
G |
Nr2f1 |
nuclear receptor subfamily 2, group F, member 1 |
multiple interactions |
ISO |
NR2F1 protein promotes the reaction [[SR 11237 co-treated with ciglitazone] results in increased expression of RARB protein] |
CTD |
PMID:12839938 |
|
NCBI chr 2:8,040,375...8,050,123
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
affects localization |
ISO |
ciglitazone affects the localization of NR3C1 protein |
CTD |
PMID:15684043 |
|
NCBI chr18:31,522,783...31,644,508
|
|
G |
Nrep |
neuronal regeneration related protein |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of NREP mRNA |
CTD |
PMID:16197558 |
|
NCBI chr18:25,291,219...25,320,742
|
|
G |
Oas1a |
2'-5' oligoadenylate synthetase 1A |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of OAS1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of OAS1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr12:35,669,798...35,680,505
|
|
G |
Optn |
optineurin |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of OPTN mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of OPTN mRNA |
CTD |
PMID:16197558 |
|
NCBI chr17:73,209,572...73,260,251
|
|
G |
Osmr |
oncostatin M receptor |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of OSMR mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 2:57,634,517...57,688,802
|
|
G |
Pakap |
paralemmin A kinase anchor protein |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PALM2AKAP2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 5:72,536,986...72,648,524 NCBI chr 5:72,313,646...72,450,645
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased cleavage of PARP1 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased cleavage of PARP1 protein]]; ciglitazone promotes the reaction [Niflumic Acid results in increased cleavage of PARP1 protein]; ciglitazone results in increased cleavage of and results in increased activity of PARP1 protein; DDIT3 mutant form inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased cleavage of PARP1 protein]]; DDIT3 mutant form inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased cleavage of PARP1 protein]]; Niflumic Acid promotes the reaction [ciglitazone results in increased cleavage of PARP1 protein] |
CTD |
PMID:15492468 PMID:21067863 |
|
NCBI chr13:94,839,484...94,871,295
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PCK1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PCK1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 3:182,348,572...182,354,521
|
|
G |
Pdzk1 |
PDZ domain containing 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PDZK1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PDZK1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 2:184,376,161...184,407,514
|
|
G |
Phka2 |
phosphorylase kinase regulatory subunit alpha 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of PHKA2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr X:37,979,629...38,102,656
|
|
G |
Phlpp1 |
PH domain and leucine rich repeat protein phosphatase 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PHLPP1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr13:22,308,532...22,530,978
|
|
G |
Pim1 |
Pim-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PIM1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PIM1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr20:7,556,496...7,560,747
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLA2G2A mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 5:156,359,725...156,362,302
|
|
G |
Plac8 |
placenta associated 8 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLAC8 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr14:9,052,601...9,074,264
|
|
G |
Plcxd1 |
phosphatidylinositol-specific phospholipase C, X domain containing 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLCXD1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr12:52,238,450...52,241,884
|
|
G |
Plin2 |
perilipin 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLIN2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PLIN2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 5:106,202,634...106,258,748
|
|
G |
Plod2 |
procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 |
decreases expression |
EXP |
ciglitazone results in decreased expression of PLOD2 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 8:93,084,548...93,167,255
|
|
G |
Plscr4 |
phospholipid scramblase 4 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLSCR4 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 8:92,987,290...93,026,056
|
|
G |
Pmm1 |
phosphomannomutase 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PMM1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 7:113,466,632...113,477,004
|
|
G |
Pnrc1 |
proline-rich nuclear receptor coactivator 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of PNRC1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 5:47,647,070...47,657,832
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of POR mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of POR mRNA |
CTD |
PMID:16197558 |
|
NCBI chr12:26,587,674...26,655,612
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions increases expression decreases expression |
ISO |
ciglitazone promotes the reaction [PPARA protein results in increased expression of PTGS2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [ciglitazone results in increased expression of PPARA mRNA]; nimesulide inhibits the reaction [ciglitazone promotes the reaction [PPARA protein results in increased expression of PTGS2 mRNA]]; nimesulide inhibits the reaction [ciglitazone results in increased expression of PPARA mRNA] ciglitazone results in decreased expression of PPARA mRNA |
CTD |
PMID:11056218 PMID:11840453 |
|
NCBI chr 7:118,712,261...118,780,723
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression increases activity increases localization affects binding decreases response to substance affects localization |
ISO EXP |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ABHD3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACAA2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACADM mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACADVL mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACSM3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of AKR1C1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of AKR1C2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ANG mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ANGPTL4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of APOL1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of APOM mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of AQP3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ARHGEF2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ATF7IP2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of BCL6 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of BDH1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of BHMT mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of BLVRB mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CAT mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CCL14 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CCL15 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CCL20 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CDH1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CIDEC mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of COBLL1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of COPA mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CSTB mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CTSC mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CYB5R3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CYP1A2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of DKK1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of DLC1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of DOK4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of EEIG1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of EFNA1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ELF5 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of FABP1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of FAM13A mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of FLNB mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GALNT2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GCN1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GK mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GK3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GPX3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GRAMD2B mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HADHA mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HAMP mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HMGCS2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HMOX1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HPN mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ITIH3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of LIPC mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of LMCD1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of LOX mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of LPCAT1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MAGED4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MAGED4B mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MAP4K3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MAPK14 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MKI67 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MTMR4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of NDRG2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of NR1H3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of NREP mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of OAS1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of OPTN mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PALM2AKAP2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PCK1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PDZK1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PHLPP1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PIM1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLA2G2A mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLAC8 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLCXD1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLIN2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLSCR4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PMM1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of POR mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PRKCD mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PSD4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of RETSAT mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of RNASE4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of RNF128 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of RPS6KC1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of S100P mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SEC23A mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SEMA3G mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SEPTIN10 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SERPINE1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SLC30A10 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SLC50A1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SNRK mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SORL1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SOWAHC mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of STBD1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SUN2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TCAF1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TIMP3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TMEM53 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TNS1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TRAF3IP2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of UGT1A6 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of UGT1A9 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of VEGFA mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of VNN1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ZNF185 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ABHD3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ACAA1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ACADM mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ACSL1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AKR1C1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AKR1C2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ANGPTL4 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AQP3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CCL14 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CCL15 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CCL20 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CDH1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CEBPD mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CHMP5 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CITED2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CYP1A2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of DOK4 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ELF5 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of EPAS1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of FABP1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of FAM13A mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of FOXO1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of GALNT2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of GPX3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HADHA mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HCAR3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HMGCS2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HMOX1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of IL1R1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of IL6ST mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ITGB5 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of JAG1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of LGALS3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of LIPC mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of LPCAT3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of MPC1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of MPZL2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of NPC1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of OAS1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of OPTN mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of OSMR mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PCK1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PDZK1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PHKA2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PIM1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PLIN2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PNRC1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of POR mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of RBMS1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of RNF10 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of S100P mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SERPINE1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SLC30A10 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SLC4A7 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SORL1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SOWAHC mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SQSTM1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of STBD1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of STX7 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of TBC1D4 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of TCAF1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of TGIF1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of TMBIM1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of VEGFA mRNA; ciglitazone binds to and results in decreased activity of PPARG protein; ciglitazone binds to and results in increased activity of PPARG protein; ciglitazone inhibits the reaction [Lipopolysaccharides results in decreased expression of PPARG mRNA]; ciglitazone promotes the reaction [PPARG protein results in increased expression of PTGS2 mRNA]; monobutyl phthalate inhibits the reaction [ciglitazone binds to and results in increased activity of PPARG protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [ciglitazone results in increased expression of PPARG mRNA]; nimesulide inhibits the reaction [ciglitazone promotes the reaction [PPARG protein results in increased expression of PTGS2 mRNA]]; nimesulide inhibits the reaction [ciglitazone results in increased expression of PPARG mRNA]; norathyriol inhibits the reaction [ciglitazone results in increased activity of PPARG protein]; PPARG promotes the reaction [ciglitazone results in increased expression of PTGS2 mRNA]; PPARG promotes the reaction [ciglitazone results in increased expression of PTGS2 protein]; PPARG protein promotes the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]]; PPARG protein promotes the reaction [ciglitazone results in increased activity of DIO2 protein]; Quercetin inhibits the reaction [ciglitazone results in increased activity of PPARG protein] ciglitazone results in increased expression of PPARG mRNA; ciglitazone results in increased expression of PPARG protein [ciglitazone binds to and results in increased activity of PPARG protein] which results in increased transport of Glucose; ciglitazone binds to and results in increased activity of PPARG protein; ciglitazone inhibits the reaction [Glycerol results in decreased expression of PPARG protein] [ciglitazone co-treated with Bucladesine] affects the expression of PPARG mRNA; [ciglitazone co-treated with Bucladesine] results in increased expression of PPARG protein; ciglitazone binds to and results in increased activity of PPARG protein; ciglitazone inhibits the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; ciglitazone inhibits the reaction [PPARG protein results in increased susceptibility to Methamphetamine]; PPARG protein promotes the reaction [ciglitazone results in increased expression of PPARGC1A mRNA] ciglitazone results in increased localization of PPARG protein PPARG protein mutant form results in decreased susceptibility to ciglitazone ciglitazone affects the localization of PPARG protein |
CTD |
PMID:11030710 PMID:11343236 PMID:11683414 PMID:11840453 PMID:12391285 PMID:12517972 PMID:12604364 PMID:12839938 PMID:12847270 PMID:14512786 PMID:14998300 PMID:15187150 PMID:15866424 PMID:16023420 PMID:16197558 PMID:16326050 PMID:16386710 PMID:16417216 PMID:16513826 PMID:16820301 PMID:17019405 PMID:18063688 PMID:18162602 PMID:18393431 PMID:19036883 PMID:19698295 PMID:19922793 PMID:20578043 PMID:21067863 PMID:21354099 PMID:21511917 PMID:21543282 More...
|
|
NCBI chr 4:150,095,743...150,221,104
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression multiple interactions |
ISO |
ciglitazone results in increased expression of PPARGC1A mRNA PPARG protein promotes the reaction [ciglitazone results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:16513826 |
|
NCBI chr14:63,073,505...63,729,215
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PRKCD mRNA |
CTD |
PMID:16197558 |
|
NCBI chr16:5,775,681...5,806,122
|
|
G |
Prodh |
proline dehydrogenase |
increases expression |
ISO |
ciglitazone results in increased expression of PRODH mRNA |
CTD |
PMID:17535976 |
|
NCBI chr11:82,910,043...82,927,305
|
|
G |
Psd4 |
pleckstrin and Sec7 domain containing 4 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PSD4 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 3:7,137,069...7,173,571
|
|
G |
Pten |
phosphatase and tensin homolog |
increases expression |
EXP |
ciglitazone results in increased expression of PTEN protein |
CTD |
PMID:20578043 |
|
NCBI chr 1:240,043,707...240,110,330
|
|
G |
Ptger3 |
prostaglandin E receptor 3 |
multiple interactions |
ISO |
[Cisplatin co-treated with ciglitazone] results in decreased expression of PTGER3 |
CTD |
PMID:21681689 |
|
NCBI chr 2:246,606,131...246,750,970
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
ISO |
[Cisplatin co-treated with ciglitazone] results in decreased expression of PTGES |
CTD |
PMID:21681689 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions affects expression increases expression |
ISO EXP |
2-chloro-5-nitrobenzanilide inhibits the reaction [ciglitazone results in increased expression of PTGS2 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [ciglitazone results in increased expression of PTGS2 protein]; [Cisplatin co-treated with ciglitazone] results in decreased expression of PTGS2; ciglitazone promotes the reaction [PPARA protein results in increased expression of PTGS2 mRNA]; ciglitazone promotes the reaction [PPARG protein results in increased expression of PTGS2 mRNA]; ciglitazone results in increased expression of and results in increased activity of PTGS2 protein; Dexamethasone inhibits the reaction [ciglitazone results in increased expression of [IL1B protein results in increased expression of PTGS2 protein]]; Dexamethasone inhibits the reaction [ciglitazone results in increased expression of and results in increased activity of PTGS2 protein]; nimesulide inhibits the reaction [ciglitazone promotes the reaction [PPARA protein results in increased expression of PTGS2 mRNA]]; nimesulide inhibits the reaction [ciglitazone promotes the reaction [PPARG protein results in increased expression of PTGS2 mRNA]]; nimesulide inhibits the reaction [ciglitazone results in increased expression of PTGS2 mRNA]; nimesulide inhibits the reaction [ciglitazone results in increased expression of PTGS2 protein]; PPARG promotes the reaction [ciglitazone results in increased expression of PTGS2 mRNA]; PPARG promotes the reaction [ciglitazone results in increased expression of PTGS2 protein] ciglitazone affects the expression of PTGS2 protein ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] ciglitazone promotes the reaction [[PAR-1-activating peptide results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; ciglitazone promotes the reaction [PAR-1-activating peptide results in increased expression of PTGS2 protein] ciglitazone results in increased expression of [IL1B protein results in increased expression of PTGS2 protein]; ciglitazone results in increased expression of PTGS2 mRNA; ciglitazone results in increased expression of PTGS2 protein |
CTD |
PMID:11840453 PMID:12031542 PMID:12517972 PMID:16417216 PMID:19954759 PMID:21067863 PMID:21681689 More...
|
|
NCBI chr13:64,714,063...64,722,320
|
|
G |
Pxdn |
peroxidasin |
decreases expression |
EXP |
ciglitazone results in decreased expression of PXDN mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 6:46,580,749...46,658,345
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
increases activity |
ISO |
ciglitazone results in increased activity of RAF1 protein |
CTD |
PMID:12083801 |
|
NCBI chr 4:150,352,158...150,412,813
|
|
G |
Rarb |
retinoic acid receptor, beta |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]]; bisphenol A diglycidyl ether inhibits the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]]; ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]; NR2F1 protein promotes the reaction [[SR 11237 co-treated with ciglitazone] results in increased expression of RARB protein]; PPARG protein promotes the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]] |
CTD |
PMID:12839938 |
|
NCBI chr15:10,837,252...11,482,037
|
|
G |
Rbms1 |
RNA binding motif, single stranded interacting protein 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of RBMS1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 3:45,195,828...45,420,406
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
decreases activity multiple interactions |
ISO |
ciglitazone results in decreased activity of RELA protein ciglitazone results in decreased activity of [RELA protein binds to NFKB1 protein] |
CTD |
PMID:17425601 |
|
NCBI chr 1:212,354,336...212,364,815
|
|
G |
Retsat |
retinol saturase |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of RETSAT mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 4:104,653,306...104,662,069
|
|
G |
Rnase4 |
ribonuclease A family member 4 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of RNASE4 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr15:26,786,287...26,803,634
|
|
G |
Rnf10 |
ring finger protein 10 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of RNF10 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr12:41,341,708...41,375,505
|
|
G |
Rnf128 |
ring finger protein 128 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of RNF128 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr X:103,183,643...103,298,431
|
|
G |
Rps6kc1 |
ribosomal protein S6 kinase C1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of RPS6KC1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr13:104,877,296...105,021,490
|
|
G |
Sec23a |
Sec23 homolog A, COPII coat complex component |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SEC23A mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 6:76,658,793...76,706,125
|
|
G |
Sema3g |
semaphorin 3G |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SEMA3G mRNA |
CTD |
PMID:16197558 |
|
NCBI chr16:6,413,589...6,425,221
|
|
G |
Septin10 |
septin 10 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SEPTIN10 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr20:27,101,764...27,194,997
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SERPINE1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SERPINE1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr12:25,237,977...25,248,356
|
|
G |
Slc24a2 |
solute carrier family 24 member 2 |
decreases expression |
EXP |
ciglitazone results in decreased expression of SLC24A2 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 5:101,497,916...101,741,840
|
|
G |
Slc24a4 |
solute carrier family 24 member 4 |
decreases expression |
EXP |
ciglitazone results in decreased expression of SLC24A4 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 6:121,279,590...121,419,811
|
|
G |
Slc30a10 |
solute carrier family 30, member 10 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SLC30A10 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SLC30A10 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr13:96,998,143...97,048,076
|
|
G |
Slc4a7 |
solute carrier family 4 member 7 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of SLC4A7 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr15:13,015,854...13,095,485
|
|
G |
Slc50a1 |
solute carrier family 50 member 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SLC50A1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 2:174,677,985...174,680,366
|
|
G |
Snrk |
SNF related kinase |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SNRK mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 8:130,657,204...130,711,461
|
|
G |
Sod3 |
superoxide dismutase 3 |
decreases expression |
EXP |
ciglitazone results in decreased expression of SOD3 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr14:62,822,865...62,828,602
|
|
G |
Sorl1 |
sortilin related receptor 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SORL1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SORL1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 8:51,238,713...51,401,458
|
|
G |
Sowahc |
sosondowah ankyrin repeat domain family member C |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SOWAHC mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SOWAHC mRNA |
CTD |
PMID:16197558 |
|
NCBI chr20:27,195,198...27,199,664
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of SQSTM1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr10:35,026,598...35,037,750
|
|
G |
Srxn1 |
sulfiredoxin 1 |
increases expression |
EXP |
ciglitazone results in increased expression of SRXN1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 3:161,064,812...161,070,372
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions increases expression |
ISO |
[Bucladesine co-treated with ciglitazone] results in increased expression of STAR mRNA; [Bucladesine co-treated with ciglitazone] results in increased phosphorylation of STAR protein; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR protein]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR protein] |
CTD |
PMID:19698295 |
|
NCBI chr16:72,969,824...72,974,447
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
bisphenol A diglycidyl ether inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; bisphenol A diglycidyl ether inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; T 0070907 inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]] |
CTD |
PMID:19922793 |
|
NCBI chr10:86,311,528...86,363,513
|
|
G |
Stbd1 |
starch binding domain 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of STBD1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of STBD1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr14:15,470,452...15,473,857
|
|
G |
Stx7 |
syntaxin 7 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of STX7 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:21,197,075...21,237,320
|
|
G |
Sun2 |
Sad1 and UNC84 domain containing 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SUN2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 7:113,155,766...113,172,950
|
|
G |
Tbc1d4 |
TBC1 domain family, member 4 |
multiple interactions increases phosphorylation |
ISO EXP |
[ciglitazone binds to PPARG protein] which results in increased expression of TBC1D4 mRNA ciglitazone results in increased phosphorylation of TBC1D4 protein |
CTD |
PMID:16197558 PMID:18063688 |
|
NCBI chr15:84,670,756...84,848,876
|
|
G |
Tcaf1 |
TRPM8 channel-associated factor 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of TCAF1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of TCAF1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 4:72,589,710...72,639,304
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
ciglitazone inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; ciglitazone inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:18162602 PMID:27936102 |
|
NCBI chr 1:90,324,312...90,340,627
|
|
G |
Tgif1 |
TGFB-induced factor homeobox 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of TGIF1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 9:110,748,094...110,757,714
|
|
G |
Thra |
thyroid hormone receptor alpha |
decreases activity |
EXP |
ciglitazone results in decreased activity of THRA protein |
CTD |
PMID:16023420 |
|
NCBI chr10:84,198,141...84,225,659
|
|
G |
Timp3 |
TIMP metallopeptidase inhibitor 3 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of TIMP3 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 7:19,408,539...19,459,558
|
|
G |
Tmbim1 |
transmembrane BAX inhibitor motif containing 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of TMBIM1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 9:75,871,835...75,889,366
|
|
G |
Tmem53 |
transmembrane protein 53 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of TMEM53 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 5:130,721,780...130,737,692
|
|
G |
Tnfrsf12a |
TNF receptor superfamily member 12A |
increases expression |
EXP |
ciglitazone results in increased expression of TNFRSF12A mRNA |
CTD |
PMID:22193206 |
|
NCBI chr10:13,211,670...13,213,666
|
|
G |
Tns1 |
tensin 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of TNS1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 9:75,491,886...75,702,853
|
|
G |
Tpm3 |
tropomyosin 3 |
increases expression |
EXP |
ciglitazone results in increased expression of TPM3 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 2:177,812,534...177,842,661
|
|
G |
Traf3ip2 |
Traf3 interacting protein 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of TRAF3IP2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr20:43,011,405...43,054,654
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
increases expression |
EXP |
ciglitazone results in increased expression of TRIB3 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 3:161,269,939...161,275,533
|
|
G |
Ucp2 |
uncoupling protein 2 |
decreases expression |
ISO |
ciglitazone results in decreased expression of UCP2 mRNA |
CTD |
PMID:11056218 |
|
NCBI chr 1:164,251,373...164,257,742
|
|
G |
Ucp3 |
uncoupling protein 3 |
decreases expression |
ISO |
ciglitazone results in decreased expression of UCP3 mRNA |
CTD |
PMID:11056218 |
|
NCBI chr 1:154,815,777...154,828,764
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of UGT1A6 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 9:96,195,018...96,256,264
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of UGT1A9 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 9:96,144,786...96,256,264
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression |
ISO |
[[Cisplatin co-treated with ciglitazone] results in decreased expression of VEGFA] which results in decreased abundance of Dinoprostone; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of VEGFA mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of VEGFA mRNA; [Cisplatin co-treated with ciglitazone] results in decreased expression of VEGFA ciglitazone results in increased expression of VEGFA mRNA |
CTD |
PMID:16197558 PMID:18599600 PMID:21681689 |
|
NCBI chr 9:22,452,854...22,468,194
|
|
G |
Vnn1 |
vanin 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of VNN1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:21,537,084...21,547,395
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression |
ISO |
ciglitazone results in decreased expression of XIAP |
CTD |
PMID:17940898 |
|
NCBI chr X:125,756,107...125,803,979
|
|
G |
Zfp185 |
zinc finger protein 185 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ZNF185 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr X:150,831,869...150,877,652
|
|